Blog

What Does the Kidney Do?

Posted by: DaVita Clinical Research

Anyone travelling on a long highway after 3 cups of coffee becomes really aware of their kidneys very quickly. But, besides getting rid of excess water, the kidney has other… Read more

An Inside Look at Risk Based Monitoring

Posted by: DaVita Clinical Research

Risk Based Monitoring (RBM) is a clinical trial-monitoring method that was developed to fulfil regulatory requirements but moves away from 100% source data verification (SDV) of patient data. RBM, in… Read more

Behind the Scenes of Clinical Research

Posted by: DaVita Clinical Research

Clinical research provides doctors important information on how to effectively treat patients, and is what makes the development of new medicines, new procedures and new tools possible. Clinical research allows… Read more

Interpreting the Guideline for Good Clinical Practice

Posted by: DaVita Clinical Research

The Guideline for Good Clinical Practice (GCP) is a set of guidelines written by the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH).  These guidelines… Read more

DCR BioReG Update

Posted by: DaVita Clinical Research

  The DaVita Clinical Research (DCR) Biorepository Grant Program (BioReG) was formed support precision-based medicine innovation in nephrology. To see an update of the BioReG Gran Program, please click the… Read more

Nephrology Research: How Will We Find a Cure?

Posted by: DaVita Clinical Research

Chances are that you or someone you know has faced a cancer diagnosis.  It’s also likely that after a diagnosis, the possibility of participating in clinical trials was highlighted. For… Read more

Enrolling Dialysis Patients for Clinical Trials

Posted by: DaVita Clinical Research

Patient enrollment for clinical trials can be a challenging task especially if the patients are dealing with a chronic illness. Dialysis patients in particular are a population that need a… Read more

How Biosimilars Could Impact Clinical Trials

Posted by: DaVita Clinical Research

Over the next few years, the patents for many therapeutic biologics will expire, allowing drug manufacturers to request US Food and Drug Administration (FDA) approval for biosimilars, medical products which… Read more